Results from UK study of the CST-Assistant show clinical relevance, cost-benefit and product-market fit
Copenhagen, Denmark, 3 September 2024– Brain+ A/S (Nasdaq First North: BRAINP) A UK usability study of the CST-Assistant has been conducted in partnership with two local Age UK sites. Both sites have used the product to support the delivery of a full CST (Cognitive Stimulation Therapy) program to a group of people with dementia. The results from the study confirm the clinical relevance and cost-benefit of the CST-Assistant. Also feedback from CST therapists and people with dementia, who participated in the study, was positive, demonstrating early product-market fit of the solution in a